. Author manuscript; available in PMC: 2019 May 1.

Published in final edited form as: Pediatr Blood Cancer. 2018 Jan 19;65(5):e26947. doi: 10.1002/pbc.26947

TABLE 4.

Best overall response, time to progression, and overall survival in pediatric patients receiving vemurafenib 720 mg or 960 mg BID

Vemurafenib dose, mg BID	Best overall response	Time to progression, months	Patient status	Overall survival, months
720	SD	4.5	Died	6.1
720	PD	2.7	Died	12.0
720	PD	2.5	Died	3.1
960	SD	9.7	Died	10.1
960	SD	5.2	Alive	16.9^a
960	SD^b	4.3	Died	5.1

BID, twice daily; PD, progressive disease; SD, stable disease.

Censored observation.

Patient had an unconfirmed partial response (observed at only one time point).